Omeros OMER
NASDAQ OMER
$19.13 +0.01 (+0.08%)
As of: Sep 4, 2026 · 3:19 PM EDT

Omeros (OMER) Non-Current Deffered Revenue (2012 - 2018)

Omeros (OMER) posted Non-Current Deffered Revenue of $8.2 million for Q4 2018, down 1.78% sequentially from $8.3 million in Q3 2018, and down 6.21% YoY from $8.7 million in Q4 2017.

Analysis

Omeros (OMER) Non-Current Deffered Revenue (2012 - 2018) Analysis & Trends

Omeros has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $8.2 million in Q4 2018.

  • Quarterly Non-Current Deffered Revenue fell 6.21% year-over-year to $8.2 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $8.2 million (down 6.21% YoY) and the FY2018 annual result came in at $8.2 million, down 6.21% from the prior year.
  • Non-Current Deffered Revenue slipped to $8.2 million in Q4 2018 per OMER's latest filing, from $8.3 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $9.2 million in Q1 2016 and troughed at $8.2 million in Q4 2018.
  • A 5-year average of $8.9 million and a median of $9.0 million in 2017 frame the typical range for Non-Current Deffered Revenue.
  • The sharpest annual moves came in 2014 and 2018: Non-Current Deffered Revenue soared 122.99% in 2014, then slipped 6.21% in 2018.
  • Over 5 years, Non-Current Deffered Revenue stood at $9.0 million in 2014, then climbed by 1.73% to $9.2 million in 2015, then retreated by 0.71% to $9.1 million in 2016, then slipped by 4.64% to $8.7 million in 2017, then retreated by 6.21% to $8.2 million in 2018.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $8.2 million, $8.3 million, and $8.5 million for Q4 2018, Q3 2018, and Q2 2018 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 138.43 Bn 130.58 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 63.34 Bn 58.15 Bn 1.37 Bn -
4 Moderna 57.98 Bn 52.85 Bn 52.00 Mn 147.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn - -
6 BeOne Medicines 39.92 Bn 34.82 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.42 Bn 32.11 Bn 992.69 Mn -
8 Royalty Pharma 28.42 Bn 27.58 Bn - -
9 Insmed 27.36 Bn 26.20 Bn 358.27 Mn -
10 Omeros 1.38 Bn 1.38 Bn 27.73 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 8.18 Mn
Sep 30, 2018 8.33 Mn
Jun 30, 2018 8.45 Mn
Mar 31, 2018 8.58 Mn
Dec 31, 2017 8.72 Mn
Sep 30, 2017 8.84 Mn
Jun 30, 2017 8.94 Mn
Mar 31, 2017 9.04 Mn
Dec 31, 2016 9.14 Mn
Sep 30, 2016 9.19 Mn
Jun 30, 2016 9.21 Mn
Mar 31, 2016 9.22 Mn
Dec 31, 2015 9.21 Mn
Sep 30, 2015 9.17 Mn
Jun 30, 2015 9.13 Mn
Mar 31, 2015 9.09 Mn
Dec 31, 2014 9.05 Mn
Sep 30, 2014 8.94 Mn
Jun 30, 2014 8.67 Mn
Mar 31, 2014 8.41 Mn